Cinctive Capital Management LP Raises Position in LivaNova PLC (NASDAQ:LIVN)

Cinctive Capital Management LP grew its stake in LivaNova PLC (NASDAQ:LIVN) by 33.3% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 206,216 shares of the company’s stock after buying an additional 51,486 shares during the quarter. Cinctive Capital Management LP’s holdings in LivaNova were worth $10,835,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Fifth Third Bancorp raised its stake in LivaNova by 97.1% in the second quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock valued at $37,000 after buying an additional 332 shares in the last quarter. Hexagon Capital Partners LLC boosted its stake in LivaNova by 117.8% during the 2nd quarter. Hexagon Capital Partners LLC now owns 684 shares of the company’s stock worth $37,000 after purchasing an additional 370 shares during the period. Lazard Asset Management LLC acquired a new position in LivaNova in the 1st quarter valued at about $84,000. Canada Pension Plan Investment Board acquired a new stake in shares of LivaNova during the second quarter worth $88,000. Finally, Central Pacific Bank Trust Division purchased a new position in LivaNova during the third quarter worth about $178,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Stock Performance

Shares of LIVN stock opened at $52.50 on Monday. The business has a 50 day simple moving average of $52.27 and a 200 day simple moving average of $52.10. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The firm has a market capitalization of $2.85 billion, a price-to-earnings ratio of 125.00 and a beta of 1.01. LivaNova PLC has a 12-month low of $42.75 and a 12-month high of $64.47.

Wall Street Analysts Forecast Growth

LIVN has been the topic of several recent analyst reports. StockNews.com lowered shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Saturday, November 16th. Needham & Company LLC reissued a “buy” rating and set a $75.00 price target on shares of LivaNova in a research report on Monday, November 25th. Mizuho reduced their price target on LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a research note on Thursday, October 31st. The Goldman Sachs Group assumed coverage on LivaNova in a report on Friday, October 4th. They issued a “buy” rating and a $65.00 target price on the stock. Finally, Robert W. Baird upped their price target on shares of LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $69.17.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.